Switch to:
ISIS Pharmaceuticals Inc (NAS:ISIS)
EV/EBIT
148.64 (As of Today)

EV/EBIT ratio is calculated as enterprise value divided by its Earnings Before Interest and Taxes (EBIT). As of today, ISIS Pharmaceuticals Inc's enterprise value is $5,908.6 Mil. ISIS Pharmaceuticals Inc's earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2015 was $39.8 Mil. Therefore, ISIS Pharmaceuticals Inc's EV/EBIT ratio for today is 148.64.

ISIS' s 10-Year EV/EBIT Range
Min: -311.1   Max: 596.9
Current: 148.67

-311.1
596.9

During the past 13 years, the highest EV/EBIT Ratio of ISIS Pharmaceuticals Inc was 596.90. The lowest was -311.10. And the median was -14.10.

ISIS's EV/EBITis ranked lower than
88% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 26.88 vs. ISIS: 148.67 )

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt). ISIS Pharmaceuticals Inc's enterprise value for the quarter that ended in Jun. 2015 was $6,550.5 Mil. ISIS Pharmaceuticals Inc's earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2015 was $39.8 Mil. ISIS Pharmaceuticals Inc's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2015 was 0.61%.


Definition

ISIS Pharmaceuticals Inc's EV/EBIT for today is calculated as:

EV/EBIT=Enterprise Value (Today)/Earnings Before Interest and Taxes (EBIT) (TTM)
=5908.595/39.75
=148.64

ISIS Pharmaceuticals Inc's current Enterprise Value is $5,908.6 Mil.
ISIS Pharmaceuticals Inc's Earnings Before Interest and Taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2015 was -20.28 (Sep. 2014 ) + 22.951 (Dec. 2014 ) + -8.485 (Mar. 2015 ) + 45.564 (Jun. 2015 ) = $39.8 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

This is a more accurate valuation of companies' operation because it consider the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt).

ISIS Pharmaceuticals Inc's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2015 is calculated as:

Earnings Yield (Joel Greenblatt) (Q: Jun. 2015 )=EBIT (TTM)/Enterprise Value (Q: Jun. 2015 )
=39.75/6550.459
=0.61 %

ISIS Pharmaceuticals Inc's Enterprise Value for the quarter that ended in Jun. 2015 was $6,550.5 Mil.
ISIS Pharmaceuticals Inc's Earnings Before Interest and Taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2015 was -20.28 (Sep. 2014 ) + 22.951 (Dec. 2014 ) + -8.485 (Mar. 2015 ) + 45.564 (Jun. 2015 ) = $39.8 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Related Terms

Enterprise Value, Earnings Yield (Joel Greenblatt), Earnings Before Interest and Taxes (EBIT)


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

ISIS Pharmaceuticals Inc Annual Data

Dec05Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14
ev2ebit -7.55-13.67-41.31-405.07-35.36-14.35-6.69-14.37-89.31-218.81

ISIS Pharmaceuticals Inc Quarterly Data

Mar13Jun13Sep13Dec13Mar14Jun14Sep14Dec14Mar15Jun15
ev2ebit -49.12-64.42-113.27-89.31-59.34-47.02-57.09-218.81-612.47164.79
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK